- Home
- OPP vs CCCC Comparison
OPP vs CCCC Comparison
Compare OPP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | CCCC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 177.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPP | CCCC |
|---|---|---|
| Price | $7.91 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 108.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.26 | $1.09 |
| 52 Week High | $8.83 | $3.65 |
Technical Indicators
Market Signals| Indicator | OPP | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 41.14 |
| Support Level | $7.90 | $1.74 |
| Resistance Level | $8.00 | $1.97 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.78 | 26.65 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.